Association of CMV, HBV, or HCV co-infection with vaccine response in adults with well-controlled HIV infection

References

• Heffernan RT, Barrett NL, Gallagher KM, Hadler JL, Harrison LH, Reingold AL, Khoshnood K, Holford TR, Schuchat A. Declining incidence of invasive Streptococcus pneumoniae infections among persons with AIDS in an era of highly active antiretroviral therapy, 1995–2000. J Infect Dis 2005; 191:2038-45; PMID:15897989; http://dx.doi.org/10.1086/430356
   PubMed Web of Science ®Google Scholar
• Cohen C, Simonsen L, Sample J, Kang JW, Miller M, Madhi SA, Campsmith M, Viboud C. Influenza-related mortality among adults aged 25–54 years with AIDS in South Africa and the United States of America. Clin Infect Dis 2012; 55:996-1003; PMID:22715173; http://dx.doi.org/10.1093/cid/cis549
   PubMed Web of Science ®Google Scholar
• Miller L, Arakaki L, Ramautar A, Bodach S, Braunstein SL, Kennedy J, Steiner-Sichel L, Ngai S, Shepard C, Weiss D. Elevated risk for invasive meningococcal disease among persons with HIV. Ann Intern Med 2014; 160:30-7; PMID:24166695; http://dx.doi.org/10.7326/P14-9011
   PubMed Web of Science ®Google Scholar
• Laurence JC. Hepatitis A and B immunizations of individuals infected with human immunodeficiency virus. Am J Med 2005; 118 Suppl 10A:75S-83S; PMID:16271546; http://dx.doi.org/10.1016/j.amjmed.2005.07.024
   PubMedGoogle Scholar
• Crum-Cianflone NF, Eberly LE, Duplessis C, Maguire J, Ganesan A, Faix D, Defang G, Bai Y, Iverson E, Lalani T, et al. Immunogenicity of a monovalent 2009 influenza A (H1N1) vaccine in an immunocompromised population: a prospective study comparing HIV-infected adults with HIV-uninfected adults. Clin Infect Dis 2011; 52:138-46; PMID:21148532; http://dx.doi.org/10.1093/cid/ciq019
   PubMed Web of Science ®Google Scholar
• Crum-Cianflone NF, Huppler Hullsiek K, Roediger M, Ganesan A, Patel S, Landrum ML, Weintrob A, Agan BK, Medina S, Rahkola J, et al. A randomized clinical trial comparing revaccination with pneumococcal conjugate vaccine to polysaccharide vaccine among HIV-infected adults. J Infect Dis 2010; 202:1114-25; PMID:20795819; http://dx.doi.org/10.1086/656147
   PubMed Web of Science ®Google Scholar
• Kourkounti S, Papaizos V, Leuow K, Kordosis T, Antoniou C. Hepatitis A vaccination and immunological parameters in HIV-infected patients. Viral Immunol 2013; 26:357-63; PMID:24044625; http://dx.doi.org/10.1089/vim.2012.0100
   PubMed Web of Science ®Google Scholar
• Murphy T, Feinstone S, Bell B. Hepatitis a vaccines. In: Plotkin O, and Offit, ed. Vaccines. China: Elsevier Saunders, 2013.
   Google Scholar
• Yao ZQ, Moorman JP. Immune exhaustion and immune senescence: two distinct pathways for HBV vaccine failure during HCV and/or HIV infection. Arch Immunol Ther Exp (Warsz) 2013; 61:193-201; PMID:23400275; http://dx.doi.org/10.1007/s00005-013-0219-0
   PubMed Web of Science ®Google Scholar
• Le Saux S, Weyand CM, Goronzy JJ. Mechanisms of immunosenescence: lessons from models of accelerated immune aging. Ann N Y Acad Sci 2012; 1247:69-82; PMID:22224726; http://dx.doi.org/10.1111/j.1749-6632.2011.06297.x
   PubMed Web of Science ®Google Scholar
• Isaguliants MG. Functionality of the immune system in patients with chronic hepatitis C: trial by superinfections and vaccinations. Expert Rev Vaccines 2007; 6:527-37; PMID:17669007; http://dx.doi.org/10.1586/14760584.6.4.527
   PubMed Web of Science ®Google Scholar
• Ferrari C. HBV and the immune response. Liver Int 2015; 35 Suppl 1:121-8; PMID:25529097; http://dx.doi.org/10.1111/liv.12749
   PubMed Web of Science ®Google Scholar
• Keeffe EB, Iwarson S, McMahon BJ, Lindsay KL, Koff RS, Manns M, Baumgarten R, Wiese M, Fourneau M, Safary A, et al. Safety and immunogenicity of hepatitis A vaccine in patients with chronic liver disease. Hepatology 1998; 27:881-6; PMID:9500723; http://dx.doi.org/10.1002/hep.510270336
   PubMed Web of Science ®Google Scholar
• Lee SD, Chan CY, Yu MI, Wang YJ, Chang FY, Lo KJ, Safary A. Safety and immunogenicity of inactivated hepatitis A vaccine in patients with chronic liver disease. J Med Virol 1997; 52:215-8; PMID:9179771; http://dx.doi.org/10.1002/(SICI)1096-9071(199706)52:2%3c215::AID-JMV16%3e3.0.CO;2-J
   PubMed Web of Science ®Google Scholar
• Wald A, Selke S, Magaret A, Boeckh M. Impact of human cytomegalovirus (CMV) infection on immune response to pandemic 2009 H1N1 influenza vaccine in healthy adults. J Med Virol 2013; 85:1557-60; PMID:23852679; http://dx.doi.org/10.1002/jmv.23642
   PubMed Web of Science ®Google Scholar
• Derhovanessian E, Theeten H, Hähnel K, Van Damme P, Cools N, Pawelec G. Cytomegalovirus-associated accumulation of late-differentiated CD4 T-cells correlates with poor humoral response to influenza vaccination. Vaccine 2013; 31:685-90; PMID:23196209; http://dx.doi.org/10.1016/j.vaccine.2012.11.041
   PubMed Web of Science ®Google Scholar
• Troy SB, Kouiavskaia D, Siik J, Kochba E, Beydoun H, Mirochnitchenko O, Levin Y, Khardori N, Chumakov K, Maldonado Y. Comparison of the immunogenicity of various booster doses of inactivated polio vaccine delivered intradermally versus intramuscularly to HIV-infected adults. J Infect Dis 2015; 211:1969-76; PMID:25567841
   PubMed Web of Science ®Google Scholar
• Nahm MH, Goldblatt D. Training manual for Enzyme linked immunosorbent assay for the quantitation of Streptococcus pneumoniae serotype specific IgG (Pn PS ELISA). (007sp Version). World Health Organization Pneumococcal Serology Reference Laboratories: WHO, 2011; Available at http://www.vaccine.uab.edu/ELISAProtocol(007sp).pdf
   Google Scholar
• Richter SS, Heilmann KP, Dohrn CL, Riahi F, Diekema DJ, Doern GV. Pneumococcal serotypes before and after introduction of conjugate vaccines, United States, 1999-2011(1.). Emerg Infect Dis 2013; 19:1074-83; PMID:23763847; http://dx.doi.org/10.3201/eid1907.121830
   PubMed Web of Science ®Google Scholar
• Wittkop L, Bitard J, Lazaro E, Neau D, Bonnet F, Mercie P, Dupon M, Hessamfar M, Ventura M, Malvy D, et al. Effect of cytomegalovirus-induced immune response, self antigen-induced immune response, and microbial translocation on chronic immune activation in successfully treated HIV type 1-infected patients: the ANRS CO3 Aquitaine Cohort. J Infect Dis 2013; 207:622-7; PMID:23204178; http://dx.doi.org/10.1093/infdis/jis732
   PubMed Web of Science ®Google Scholar
• Derhovanessian E, Larbi A, Pawelec G. Biomarkers of human immunosenescence: impact of Cytomegalovirus infection. Curr Opin Immunol 2009; 21:440-5; PMID:19535233; http://dx.doi.org/10.1016/j.coi.2009.05.012
   PubMed Web of Science ®Google Scholar
• Naeger DM, Martin JN, Sinclair E, Hunt PW, Bangsberg DR, Hecht F, Hsue P, McCune JM, Deeks SG. Cytomegalovirus-specific T cells persist at very high levels during long-term antiretroviral treatment of HIV disease. PLoS One 2010; 5:e8886; PMID:20126452; http://dx.doi.org/10.1371/journal.pone.0008886
   PubMed Web of Science ®Google Scholar
• Khan N, Hislop A, Gudgeon N, Cobbold M, Khanna R, Nayak L, Rickinson AB, Moss PA. Herpesvirus-specific CD8 T cell immunity in old age: cytomegalovirus impairs the response to a coresident EBV infection. J Immunol 2004; 173:7481-9; PMID:15585874; http://dx.doi.org/10.4049/jimmunol.173.12.7481
   PubMed Web of Science ®Google Scholar
• Barton ES, White DW, Cathelyn JS, Brett-McClellan KA, Engle M, Diamond MS, Miller VL, Virgin HW 4th. Herpesvirus latency confers symbiotic protection from bacterial infection. Nature 2007; 447:326-9; PMID:17507983; http://dx.doi.org/10.1038/nature05762
   PubMed Web of Science ®Google Scholar
• Yager EJ, Szaba FM, Kummer LW, Lanzer KG, Burkum CE, Smiley ST, Blackman MA. gamma-Herpesvirus-induced protection against bacterial infection is transient. Viral Immunol 2009; 22:67-72; PMID:19210230; http://dx.doi.org/10.1089/vim.2008.0086
   PubMed Web of Science ®Google Scholar
• Furman D, Jojic V, Sharma S, Shen-Orr SS, Angel CJ, Onengut-Gumuscu S, Kidd BA, Maecker HT, Concannon P, Dekker CL, et al. Cytomegalovirus infection enhances the immune response to influenza. Sci Transl Med 2015; 7:281ra43; PMID:25834109; http://dx.doi.org/10.1126/scitranslmed.aaa2293
   PubMed Web of Science ®Google Scholar
• den Elzen WP, Vossen AC, Cools HJ, Westendorp RG, Kroes AC, Gussekloo J. Cytomegalovirus infection and responsiveness to influenza vaccination in elderly residents of long-term care facilities. Vaccine 2011; 29:4869-74; PMID:21497631; http://dx.doi.org/10.1016/j.vaccine.2011.03.086
   PubMed Web of Science ®Google Scholar
• O'Connor D, Trück J, Lazarus R, Clutterbuck EA, Voysey M, Jeffery K, Pollard AJ. The effect of chronic cytomegalovirus infection on pneumococcal vaccine responses. J Infect Dis 2014; 209:1635-41; PMID:24302755; http://dx.doi.org/10.1093/infdis/jit673
   PubMed Web of Science ®Google Scholar
• Ye B, Liu X, Li X, Kong H, Tian L, Chen Y. T-cell exhaustion in chronic hepatitis B infection: current knowledge and clinical significance. Cell Death Dis 2015; 6:e1694; PMID:25789969; http://dx.doi.org/10.1038/cddis.2015.42
   PubMed Web of Science ®Google Scholar
• Cho HC, Kim YJ, Choi MS, Lee JH, Koh KC, Yoo BC, Paik SW. The seroconversion rate of hepatitis A virus vaccination among patients with hepatitis B virus-related chronic liver disease in Korea. Gut Liver 2011; 5:217-20; PMID:21814604; http://dx.doi.org/10.5009/gnl.2011.5.2.217
   PubMed Web of Science ®Google Scholar
• Tsang SW, Sung JJ. Inactivated hepatitis A vaccine in Chinese patients with chronic hepatitis B infection. Aliment Pharmacol Ther 1999; 13:1445-9; PMID:10571600; http://dx.doi.org/10.1046/j.1365-2036.1999.00628.x
   PubMed Web of Science ®Google Scholar
• Majda-Stanislawska E, Bednarek M, Kuydowicz J. Immunogenicity of inactivated hepatitis A vaccine in children with chronic liver disease. Pediatr Infect Dis J 2004; 23:571-4; PMID:15194843; http://dx.doi.org/10.1097/01.inf.0000130076.33497.6c
   PubMed Web of Science ®Google Scholar
• Lederman MM, Funderburg NT, Sekaly RP, Klatt NR, Hunt PW. Residual immune dysregulation syndrome in treated HIV infection. Adv Immunol 2013; 119:51-83; PMID:23886064; http://dx.doi.org/10.1016/B978-0-12-407707-2.00002-3
   PubMed Web of Science ®Google Scholar
• Okulicz JF, Le TD, Agan BK, Camargo JF, Landrum ML, Wright E, Dolan MJ, Ganesan A, Ferguson TM, Smith DM, et al. Influence of the timing of antiretroviral therapy on the potential for normalization of immune status in human immunodeficiency virus 1-infected individuals. JAMA Intern Med 2015; 175:88-99; PMID:25419650; http://dx.doi.org/10.1001/jamainternmed.2014.4010
   PubMed Web of Science ®Google Scholar